Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,751 active trials43 approved drugs423 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,697 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,318)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04570956 | Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk | terminated | Phase 2 | 65 | Mayo ClinicOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05908786 | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 62 | Hoffmann-La RocheINDUSTRY | 6 | Sep 15, 2026 | clinicaltrials |
| NCT04191135 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) | terminated | Phase 2 | 462 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Sep 14, 2026 | clinicaltrials |
| NCT05756166 | Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | Roswell Park Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT03442556 | Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency | terminated | Phase 2 | 18 | University of WashingtonOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT01216371 | Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)(SMAT) | terminated | Phase 2 | 60 | Association of Urologic Oncology (AUO)OTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04019327 | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | terminated | Phase 1 / Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03274258 | Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma | terminated | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05435014 | T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 2 | T-ACE Medical Co., LtdINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05286827 | Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Aug 14, 2026 | clinicaltrials |
| NCT03991130 | High Dose IL-2 in Combination With Anti-PD-1 | terminated | Phase 2 | 6 | Gregory DanielsOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05199285 | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab | terminated | Phase 2 | 15 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03695250 | BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 8 | Edward KimOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05689021 | CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations | terminated | Phase 2 | 8 | Mayo ClinicOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | terminated | Phase 1 / Phase 2 | 14 | TCR2 TherapeuticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04331067 | Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer | terminated | Phase 1 / Phase 2 | 15 | Washington University School of MedicineOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04216472 | Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer | terminated | Phase 2 | 17 | University of Southern CaliforniaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03630640 | Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation(NIVOLEP) | terminated | Phase 2 | 43 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04975516 | Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer | terminated | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05537402 | LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC(LOST-B) | terminated | Phase 2 | 1 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | terminated | Phase 2 | 77 | Regeneron PharmaceuticalsINDUSTRY | 2 | Jun 9, 2026 | clinicaltrials |
| NCT04955743 | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma | terminated | Phase 2 | 18 | Yale UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | GenmabINDUSTRY | 2 | Jun 1, 2026 | clinicaltrials |
| NCT06844669 | HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy | terminated | Phase 2 | 7 | Washington University School of MedicineOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05027425 | Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant | terminated | Phase 2 | 8 | University of CincinnatiOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06617455 | Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial(VEnT) | terminated | Phase 2 | 9 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04034251 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05103904 | Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant | terminated | Phase 2 | 3 | Emory UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT02874430 | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer | terminated | Phase 2 | 29 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT04387071 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma | terminated | Phase 1 / Phase 2 | 2 | University of Southern CaliforniaOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07040059 | A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | terminated | Phase 1 / Phase 2 | 2 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05567835 | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer(TOGAR) | terminated | Phase 2 | 3 | Baylor College of MedicineOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03727633 | Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion(LIDA-BII) | terminated | Phase 2 | 44 | University Hospital, MontpellierOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04904302 | Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer | terminated | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03360721 | Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03753919 | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial(DUTHY) | terminated | Phase 2 | 79 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04327700 | Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib | terminated | Phase 2 | 2 | Wake Forest University Health SciencesOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06114940 | Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)(PLUTO) | terminated | Phase 2 | 17 | Jinling Hospital, ChinaOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) | terminated | Phase 1 / Phase 2 | 42 | GenmabINDUSTRY | 2 | Mar 4, 2026 | clinicaltrials |
| NCT05554354 | Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 2 | Mar 3, 2026 | clinicaltrials |
| NCT05676463 | MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer | terminated | Phase 2 | 6 | Thomas Jefferson UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03801369 | AMTEC IIT: Phase 2 Multiarm Study in TNBC | terminated | Phase 2 | 24 | Gordon Mills, MD, PhDOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03785210 | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers | terminated | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2026 | clinicaltrials |
| NCT06851104 | A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence | terminated | Phase 2 | 45 | Guangxi Medical UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03101748 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials